相似文献
1
No recurrence of Pneumocystis jirovecii Pneumonia after solid organ transplantation regardless of secondary prophylaxis.
Antimicrob Agents Chemother. 2012 Nov;56(11):6041-3. doi: 10.1128/AAC.00998-12. Epub 2012 Sep 4.
2
Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Transpl Infect Dis. 2018 Dec;20(6):e12984. doi: 10.1111/tid.12984. Epub 2018 Sep 19.
3
Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
Transpl Infect Dis. 2018 Jun;20(3):e12876. doi: 10.1111/tid.12876. Epub 2018 Mar 31.
4
Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00173-18. Print 2018 Aug.
5
Late-onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients.
Transpl Infect Dis. 2014 Apr;16(2):324-8. doi: 10.1111/tid.12184. Epub 2014 Jan 24.
6
Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors.
J Pediatr Hematol Oncol. 2017 Apr;39(3):194-202. doi: 10.1097/MPH.0000000000000771.
7
Current Concepts in the Diagnosis and Management of Pneumocystis Pneumonia in Solid Organ Transplantation.
Infect Dis Clin North Am. 2023 Sep;37(3):617-640. doi: 10.1016/j.idc.2023.03.005. Epub 2023 May 2.
8
The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
BMC Infect Dis. 2016 Feb 25;16:90. doi: 10.1186/s12879-016-1432-3.
9
Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
Transpl Infect Dis. 2020 Apr;22(2):e13245. doi: 10.1111/tid.13245. Epub 2020 Jan 24.
10
Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12769. Epub 2017 Oct 25.
引用本文的文献
1
Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study.
Intern Med. 2022 Apr 1;61(7):997-1006. doi: 10.2169/internalmedicine.8205-21. Epub 2021 Sep 11.
2
An Approach to a Pulmonary Infiltrate in Solid Organ Transplant Recipients.
Curr Fungal Infect Rep. 2015;9(3):144-154. doi: 10.1007/s12281-015-0229-y. Epub 2015 Jul 11.
本文引用的文献
1
Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients.
Nephrol Dial Transplant. 2011 Jun;26(6):2013-7. doi: 10.1093/ndt/gfq689. Epub 2010 Nov 11.
2
Pneumocystis pneumonia in solid organ transplant recipients.
Am J Transplant. 2009 Dec;9 Suppl 4:S227-33. doi: 10.1111/j.1600-6143.2009.02914.x.
3
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4.
4
Mycophenolate mofetil may protect against Pneumocystis carinii pneumonia in renal transplanted patients.
Rev Inst Med Trop Sao Paulo. 2005 May-Jun;47(3):143-5. doi: 10.1590/s0036-46652005000300005. Epub 2005 Jul 12.
5
Pneumocystis pneumonia.
N Engl J Med. 2004 Jun 10;350(24):2487-98. doi: 10.1056/NEJMra032588.
6
Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study.
Transpl Infect Dis. 2003 Jun;5(2):84-93. doi: 10.1034/j.1399-3062.2003.00018.x.
7
Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
Clin Infect Dis. 2003 Mar 1;36(5):645-51. doi: 10.1086/367659. Epub 2003 Feb 12.
8
Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.
Clin Infect Dis. 2002 Apr 15;34(8):1098-107. doi: 10.1086/339548. Epub 2002 Mar 21.
9
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
N Engl J Med. 2001 Jan 18;344(3):159-67. doi: 10.1056/NEJM200101183440301.
10
Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.
Clin Infect Dis. 2000 Apr;30 Suppl 1:S5-14. doi: 10.1086/313843.
Zotero 插件